Boehringer Ingelheim is to refocus its efforts on schizophrenia after its investigational compound did meet its efficacy endpoints in Phase II Alzheimer’s disease trials.
The company will now explore the potential of compounds BI 409306 and BI 409306 in schizophrenia trials.
These Alzheimer’s disease trials were part of an extensive clinical trial programme exploring the efficacy of compounds which target malfunctioning of specific (glutamatergic) brain circuits as potential new treatments for specific symptoms and traits of a mental illness.
As such, the investigational compound BI 409306 was explored in patients with cognitive impairment and those with memory dysfunction in schizophrenia and in Alzheimer’s disease.
Further investigations will focus on two studies in schizophrenia, aimed at prevention of relapse and at prevention of occurrence of a first psychotic episode.
Boehringer Ingelheim’s continued engagement in the dementia field is confirmed by the planned phase II trials investigating another compound, BI 425809, a GlyT1 inhibitor, in a range of central nervous system indications which also include Alzheimer’s disease.
Following a comprehensive review of the complete trial data, Boehringer Ingelheim intends to present the full results at the Alzheimer’s Association International Conference 2018 in July.